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RadiotherapyAbstract Gall bladder carcinoma (GBC) is considered the ﬁfth most common one of the most
aggressive gastro intestinal tract malignancies. Owing to their large incidence randomised controlled
trials have hardly been conducted to look into their optimum treatment. Over the years surgical
resection has been considered the only curative treatment of these tumors. However, the outcome
still remains guarded. The predominant pattern of failure is loco-regional followed by systemic.
Hence, local adjuvant radiation has been used by different institutes with concurrent and adjuvant
chemotherapy. The large retrospective series with their limitations showed improved survival in
patients with regional spread or tumors inﬁltrating the liver when treated with adjuvant radiother-
apy. In the present era with modern radiation techniques and target delineation radiation may fur-
ther improve upon the impact without adding to the toxicity proﬁle. Hence, radiation in gall
bladder cancer needs a relook to optimize treatment outcome of such aggressive disease.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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2 S. Mallick et al.Introduction
Gall bladder carcinoma (GBC) is considered the ﬁfth most
common and one of the most aggressive gastro intestinal tract
malignancies [1,2]. Most of the GBC0s are adenocarcinoma
arising from the epithelium. GBC has been reported to be three
to ﬁve times more common in females than males. The patho-
genesis of GBC has been explained by two hypothesis, gall
stone-cholecystitis (relative risk of 4.9) and anomalous biliary
ducts [3].
Owing to the incidence randomised controlled trials have
hardly been conducted to look into the optimum treatment.
Therefore, the treatment decisions are derived from retrospec-
tive studies and small prospective cohort studies which should
be interpreted with caution. Over the years surgical resection
has been considered the only curative treatment of these
tumors. However, even after a good surgical resection the med-
ian survival does not exceed 14–15 months in most of the
reported series. Hence, adjuvant therapy appears very much
logical for better tumor control and for better survival.
Optimum surgery in GBC
Surgery is considered as the only deﬁnitive treatment for
non-metastatic gall bladder cancer. Simple cholecystectomy
includes removal of the gall bladder only. Extended chole-
cystectomy includes cholecystectomy, en bloc hepatic lobe
IVB and V resection, and nodal resection [4]. The extent
of surgical resection is often guided by the factors like, inﬁl-
tration of liver, involvement of portal structures and nodal
involvement.
Simple cholecystectomy is considered adequate for tumors
limited to the lamina propria [T1a] only. In all other cases
an extended cholecystectomy is recommended [T1b onward].
Matsumoto et al. compared 3 year survival of Stage II GBC
treated with simple vs. radical cholecystectomy [5]. The
authors reported a three year survival of 29–57% vs. 100%
favoring radical cholecystectomy making radical cholecystec-
tomy the standard surgical procedure in Stage II GBC.
However, in Stage III and Stage IV the three year survival ran-
ged from 7% to 80% even after extended surgical resection [6].
The beneﬁt with radical cholecystectomy was close to statisti-
cal signiﬁcance in multivariate analysis.
Achieving an R0 resection is important to improve survival
outcomes of GBC patients [7]. In a study by Itoh et al. it was
found that overall 5-year survival rates of gall bladder carci-
noma patients were 73%, 40%, and 0% for R0, R1 and R2,
respectively [8]. The importance of R0 resection in survival
has also been shown in other studies [9]. The high rates of loco
regional failures in addition to systemic metastasis despite an
R0 resection have been attributed to the dismal prognosis in
GBC. Therefore, adjuvant radiation or chemo-radiation has
been adopted in many centers to optimize tumor control and
thereby improve survival.
Dose radiation has a role after R0 resection
Bosset et al. was one of the ﬁrst to report the beneﬁt of adju-
vant radiotherapy in GBC [10]. They reported the outcome of
7 patients who received adjuvant radiotherapy after complete
surgery for gall bladder cancer. When they initially publishedtheir data in 1989 after a minimum follow up of 5 months 5
out of the 7 patients were alive with no evidence of disease.
Thus they advocated the use of post-operative adjuvant radio-
therapy after complete surgery for GBC.
Czito et al. retrospectively analyzed outcomes of 22 patients
who received adjuvant radiotherapy after deﬁnitive surgery in
patients of non-metastatic GBC [11]. Out of the 22 patients 18
received chemotherapy in addition. The radiotherapy dose was
45 Gy and volume included tumor bed and local–regional
lymph nodes. The analysis of their data with a median follow
up of 1.7 years, revealed 5-year actuarial overall survival of
37%, disease-free survival of 33%, metastases-free survival
of 36%, and local–regional control of 59%. Patients who
had extended resection experienced improved survival com-
pared with patients who had simple cholecystectomy although
it was not statistically signiﬁcant probably due to small sample
size of the study.
Yang et al. reported a retrospective single institute experi-
ence of treating 127 gall bladder patients [12]. 84 patients in
this series underwent radical resection alone, while 43 patients
underwent radical resection with adjuvant radiotherapy. The
median survival time of patients who underwent surgery and
postoperative radiotherapy was 16.9 months, and the 1 year,
3 year, and 5 year survival rates were signiﬁcantly higher than
that of the simple operation group. They concluded that sur-
vival rates of the postoperative radiotherapy group were
higher than the surgical resection alone group.
Gold et al. did a retrospective review of 73 GBC patients
who underwent R0 resection [13]. The study included patients
of T1-T3N0-1 post op patients of GBC of which, 25 underwent
surgery and adjuvant therapy while 48 underwent surgery
only. The median radiation dose used in this study was
50.4 Gy (range, 19.75–54.0) and multiple-ﬁeld techniques were
used in treatment delivery. It was seen that median OS was not
different in patients undergoing surgery and adjuvant
chemoradiotherapy vs. surgery alone. But the study must be
analyzed with caution as 22% of the patients in the study were
having T1 disease and lymph nodes were not addressed in 17%
of the patients.
Kresl et al. also did a retrospective review of 21 GBC
patients who underwent adjuvant chemoradiotherapy at the
Mayo Clinic [14]. The study included 1 patient of Stage I and
20 patients of Stage III/IV. The median radiation dose was
54 Gy (range 50.4–60.8 Gy) and concurrent 5-ﬂuorouracil
was used with radiotherapy. They had found that a 5-year sur-
vival rate of 64% for the patients treated with this approach
and the results were superior to historical surgical controls
from the Mayo Clinic. Tumor stage and extent of resection
was shown to be important factors that inﬂuence survival and
local control in these patients. Thus their data showed a prob-
able beneﬁt of adding adjuvant chemoradiotherapy in GBC
after surgical resection.
Itoh et al. retrospectively analyzed data of 18 patients with
GBC using the Cox regression method for predictors of sur-
vival in GBC [8]. They could not ﬁnd any signiﬁcant difference
in the 5-year survival rate between the resection and radiother-
apy vs. resection alone for GBC. Direct invasion of liver par-
enchyma was seen to be a predictor of survival in GBC
patients on multivariate analysis.
Agrawal et al. retrospectively analyzed single institute data
of 32 patients with GBC who were treated with surgery adju-
vant radiotherapy and adjuvant chemotherapy [15]. With this
Adjuvant radiotherapy in the treatment of Gall bladder carcinoma 3approach they could achieve 5 year OS and DFS of 25% and
53%, respectively. It was also found that node positive disease,
stage of disease, R1 resection; poorly differentiated tumours
were associated with poorer survival outcomes. In another ser-
ies Jeong et al. retrospectively analyzed 86 patients with GBC
who underwent surgical resection followed by postoperative
radiotherapy [16]. They reported 5 year OS, DFS and LRC
rates of 42%, 36% and 73%, respectively using this standard
approach. Postoperative carbohydrate antigen 19.9 level was
found to be a signiﬁcant prognostic factor in patients with
GBC on multivariate analysis.
The SWOG S0809 was a phase II trial which evaluated the
role of adjuvant chemotherapy followed by radiotherapy with
concurrent capecitabine in cholangiocarcinoma and GBC [17].
The trial included 79 patients of whom 25 were GBC patients.
Using the protocol of adjuvant chemotherapy followed by
chemoradiotherapy the median overall survival was
35 months. The most common grade 3 to 4 adverse effects
were neutropenia followed by hand–foot syndrome and
diarrhea.
Wang et al. constructed prediction model for estimating
the survival beneﬁt of adjuvant radiotherapy using data from
4180 patients with resected gall bladder from the SEER data-
base [18]. Multivariate regression analysis using this model
showed that age, sex, papillary histology, stage and adjuvant
RT are signiﬁcant predictors of OS. The 2-year, and 5-year
overall survival rates for the entire patient cohort were
30%, and 17%, respectively. The analysis predicted that
adjuvant RT provides a survival beneﬁt in node-positive
and patients with T2 disease.
Horgan et al. conducted a systematic review and meta-
analysis of published institutional and registry data to evaluate
the beneﬁt of adjuvant therapy for biliary tract cancer [19]. The
meta-analysis included twenty studies involving 6712 patients.
The authors reported a non-signiﬁcant beneﬁt with adjuvant
therapy vs. surgery alone. The survival was found better in
patients treated with chemo-radiotherapy compared with
radiotherapy alone. The beneﬁt was signiﬁcantly higher for
node positive and R1 resection.
Hyder et al. analyzed the SEER data base to deﬁne the role of
adjuvant radiotherapy for GBC [20]. The authors identiﬁed 5011
patients with GBC who underwent surgical resection from 1998
to 2009. Seventy-ﬁve percentage had a localized disease and only
17.9% patients received adjuvant radiation. Adjuvant radiation
was used mostly for younger age, tumor extension beyond the
serosa, intermediate to poorly differentiated tumors and patients
with lymph node metastasis. In a propensity matched multivari-
ate analysis the authors reported signiﬁcantly improved 1 year
survival with the use of adjuvant radiotherapy and the survival
beneﬁt was more pronounced for N1 disease and moderately-
poorly differentiated tumors. However, the beneﬁt was not sig-
niﬁcant at 5 years. A previous SEER data base analysis by
Mojica et al. had also shown that adjuvant radiotherapy was
associated with improved survival in patients with regional
spread or tumors inﬁltrating the liver [21]. Table 1 summarizes
all studies reporting results of adjuvant radiation in GBC.
Addition of chemotherapy to radiotherapy in adjuvant GBC
Systemic failure is the commonest mode of recurrence in GBC,
reported in as high as 80% of cases [22]. Preventing thesystemic relapse is an area of active research to improve out-
comes. The best logical way to achieve it is through systemic
chemotherapy. Gall bladder cancer is not a very chemo sensi-
tive disease but most of the studies which have shown the ben-
eﬁt of adjuvant radiotherapy include concurrent chemotherapy
also. Hence chemotherapy must be added to the adjuvant
radiotherapy protocols whenever possible.
Fluorouracil is the most commonly used drug in the concur-
rent setting in GBC. Its efﬁcacy and safety has been proven in
various trials and must be the preferred agent in concurrent set-
ting. Capecitabine an oral analog of ﬂuorouracil may be a log-
ical substitution and has been proven to be equally effective as
ﬂuorouracil in various gastro intestinal malignancies.
Gemcitabine is another agent that has proven its efﬁcacy in
metastatic GBC and has possible radio sensitizing effect and
may be considered in concurrent setting [23]. But the high tox-
icity associated with gemcitabine when given concurrently with
radiotherapy as shown in pancreatic cancers must be kept in
mind when advising gemcitabine concurrent with radiotherapy.
Radiotherapy volumes and optimal dose
The pattern of local recurrence and nodal distribution will help
us in deﬁning the target volumes in post-operative radiother-
apy in gall bladder cancers. The primary nodal drainage is to
lymph nodes along the cystic and common bile ducts then they
spread to pancreaticoduodenal nodes and to the para aortic
nodes. Of all the relapsing patients 45% have some component
of local–regional relapse. The main sites of isolated loco regio-
nal recurrence in GBC are hilum, anastomotic site, resection
margin of liver and the retroperitoneal lymph nodes [22].
Matsumoto et al. evaluated the lymph node metastasis and
classiﬁed cystic, peridochal and hilar lymph node as group 1,
peripancreatic, portal and hepatic group of nodes as group 2
and celiac, peri duodenal and peri-mesenteric as group 3.
The authors reported 17%, 18.8% and 14.5% risk of lymph
node metastasis in group 1, 2 and 3, respectively.
The post-operative radiotherapy volumes must include the
tumor bed and the regional lymph nodes. The regional lymph
nodes must include the porta hepatis, celiac, para-aortic, and
pancreaticoduodenal nodes. The CTV primary includes the
GB fossa as evident in the pre-operative CECT image and
the surgical clips with 1 cm isotropic expansion.
The portal vein should be delineated from the conﬂuence of
superior mesenteric vein and the splenic vein to the bifurcation
in two right and left hepatic veins. The celiac axis should be
delineated for proximal 1.5–2 cm. An isotropic 1 cm expansion
should be added to generate the lymph node station. The aorta
should be delineated from at least 1 cm cranial to the CTV pri-
mary or portal lymph node station extending to the L2 level.
An asymmetric expansion, 3–3.5 cm to the right, 2–2.5 cm
anteriorly, 1–1.5 cm to the left and 0.2 cm posteriorly should
be added to generate the aorto-caval group lymph node. The
pancreaticoduodenal lymph nodes should be contoured by giv-
ing 10 mm margin around the anterior and posterior pancre-
aticoduodenal artery. These should be then fused to form the
nodal CTV (Figs. 1 and 2).
Adoseof 45 Gy in25 fractionsover 5 weeksmaybeacceptable
and has been shown to improve outcome in patients withGBC.A
boost of 5.4 Gymay be considered in an R1 resection. A boost of
15 Gy may be given in cases of gross residual lesion [24].
Table 1 Summarizes the available literature which reported the effect of adjuvant radiation in gall bladder cancer [EBRT, external beam radiotherapy; IORT, intraoperative
radiotherapy].
Author No of patients Radiotherapy dose Radiotherapy volume Toxicity Concurrent
Chemotherapy
Outcomes
Bosset [10] 7 46 Gy – Moderate acute side eﬀects
were seen in ﬁve patients
Nil 5 patients alive at minimum follow up of
5 months
Czito [11] 22
T2 N1 onwards
45 Gy Tumor bed and local–
regional lymph nodes (porta
hepatis, pericholedochal,
celiac, and
pancreaticoduodenal)
Concurrent
5-ﬂuorouracil
(5-FU)
5-Year overall and disease-free survivals
were 37% and 33%
Yang [12] 127
84 cases –radical resection
43 cases – radical resection
with post op radiotherapy
– – Nausea, vomiting and
abdominal
Pain-relieved on supportive
therapy
Nil 1 year survival rates – 14.2% and 9.8%
5 year survival rates – 7.2% and 1.9%
[statistically signiﬁcant in favor of
adjuvant RT arm]
Gold [13] 73
T1-T2N0M0
T3N0M0 or T1-T3N1M0
50.4 Gy –median Gallbladder fossa and
regional lymph nodes
(45.0 Gy in 25 fractions) with
a boost to the gallbladder
fossa (total dosage, 50.4 Gy)
The regional lymph nodes
included the porta hepatis,
celiac, para-aortic, and
pancreaticoduodenal nodes
Treatment related death in 2
patients
Concurrent
5-ﬂuorouracil
Median OS not diﬀerent in patients
receiving adjuvant chemoradiotherapy
or surgery alone
Kresl [14] 21
Stage I-1
Stage III–IV-20
54 Gy (range
50.4–60.8 Gy)
Tumor bed and regional
lymph nodes (porta hepatis,
celiac, pancreatico-duodenal)
Chronic toxicity developed
in 2 patients
Concurrent
5-ﬂuorouracil
5-Year survival rate of 64%
Lindell [26] 20
10 received RT
EBRT± IORT IORT/EBRT is safe to be
added in adjuvant GBC
Nil 5-Year survival was 47% in the
radiotherapy group and 13% in surgery
only group [statistically non-signiﬁcant]
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Figure 1 Target volume delineation in a case of gall bladder cancer and dose color wash in a 3DCRT plan of GBC.
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ning in GBC are the liver and the right kidney. Another
organ at risk whose tolerance must be kept in mind is the
spinal cord. A computed tomography based 3 dimensional
conformal radiotherapy should be used. A three ﬁeld
technique may be the optimum ﬁeld arrangement and using
differential weightage of these beams irradiation of these
volumes while maintaining the tolerance of the organs at risk
may be achieved. The left lateral beam may be delivered
by higher energy photons like 15 MV or 18 MV to further
optimize the plan.
We must try to limit the mean dose of the liver to less than
30 Gy and the volume of liver receiving 30 Gy to less than
60%. The kidney mean dose must be kept below 16–18 Gy
volume of the kidney and receiving 20 Gy to less than 66%.
We may also try to restrict the volume of both kidneys
combined receiving 20 Gy to less than 75%. The maximum
dose to the spinal cord may be preferentially kept below 45 Gy.Figure 2 Dose volume histogram depicting conformal dose deliNewer radiotherapy techniques
Over the last decade the radiotherapy technique has witnessed
a paradigm shift from 2D planning to conformal radiation
with an aim to optimize tumor control and minimize both
acute and chronic radiation morbidity. The improvement in
radiation delivery with intensity modulated radiotherapy
(IMRT), image guided radiotherapy has further paved the
way for exploration of adjuvant radiation for GBC.
Fuller et al. in a series of 24 patients highlighted the feasibility
of image guided intensity to modulate radiotherapy [IGIMRT]
for GBC with minimal radiation morbidity [25]. The target
localization in this study was done using ultrasonography.
The use of image guidance in radiotherapy helps in reducing
set up errors and thereby reduces the PTVmargins. No patients
completing the IGIMRTprotocol had any grade 3 lowerGI tox-
icity. The IGIMRT arm experienced a better survival compared
to the 3DCRTarm though not statistically signiﬁcant. Thus, it0svery without compromising dose tolerance of adjacent organ.
6 S. Mallick et al.worth exploring IGIMRT for radiation delivery in the adjuvant
setting forGBC to optimize local disease control with dose esca-
lation and better sparing of organ at risk.
Conclusion
In the absence of phase III data it is difﬁcult to get level-I evi-
dence for adjuvant radiotherapy. Radiotherapy must be used as
an adjuvant therapy in resected cases of GBC when the disease
is T2 or node positive to reduce local recurrence and to improve
survival with the current available best evidence. It must be
combined with chemotherapy in all feasible patients to improve
local control and to reduce distant recurrences. With the avail-
ability of newer sophisticated radiation techniques it may be
feasible to deliver adequate dose to the target while keeping
the organs at risk within tolerable limits. There is also a feasi-
bility of increasing the dose to by using image guidance and bet-
ter radiation delivery techniques. A multicenter phase III trial
may help us in giving a deﬁnite answer regarding the role of
radiotherapy in adjuvant treatment of GBC.
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